Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
Pharmacists on the frontline in Victoria’s COVID-19 surge
Victorian pharmacists are once again stepping up in response to the COVID-19 pandemic, as residents in greater Melbourne and the Mitchell Shire prepare for the reintroduction of Stage 3 restrictions for six weeks from midnight tonight (8 July).
Restoring faith in sun safety
Investigations reveal many popular sunscreens don’t live up to their labels. But pharmacists can promote holistic sun protection.
Potential treatments for COVID-19
As confirmed COVID-19 cases soar well past 3 million worldwide, the race is on to find treatments for patients as soon as possible.
Pharmacists at forefront of Australia’s vaccine rollout
Pharmacists were among the first to receive the COVID-19 vaccine on Monday in what has been labelled a ‘momentous day’ in Australia’s history.
Alfred Health...
Difficult patients: Calming the storm
Dealing with aggressive or abusive patients is one of the least pleasant components of a community pharmacist’s role. What’s best practice for avoiding or...
Pharmacists supporting patients with palliative care needs
For many, the last 12 months of life is spent with significant disability, associated with rising symptom burden and functional decline. A palliative approach...
